[HTML][HTML] Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C
S Tanwar, F Rhodes, A Srivastava… - World journal of …, 2020 - ncbi.nlm.nih.gov
At present chronic liver disease (CLD), the third commonest cause of premature death in the
United Kingdom is detected late, when interventions are ineffective, resulting in …
United Kingdom is detected late, when interventions are ineffective, resulting in …
Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives
R Wilkens, KL Novak, C Maaser… - Therapeutic …, 2021 - journals.sagepub.com
Treatment targets of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's
disease (CD) have evolved over the last decade. Goals of therapy consisting of symptom …
disease (CD) have evolved over the last decade. Goals of therapy consisting of symptom …
Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality
Y Wang, H Rao, X Chi, B Li, H Liu, L Wu, H Zhang… - …, 2019 - thelancet.com
Background Whether achieving sustained virological response (SVR) in patients with
hepatitis C attains complete elimination of hepatitis C virus (HCV) is unknown, because …
hepatitis C attains complete elimination of hepatitis C virus (HCV) is unknown, because …
Molecular mechanisms of hepatocarcinogenesis following sustained virological response in patients with chronic hepatitis C virus infection
CN Hayes, P Zhang, Y Zhang, K Chayama - Viruses, 2018 - mdpi.com
Despite the success of direct-acting antiviral (DAA) agents in treating chronic hepatitis C
virus (HCV) infection, the number of cases of HCV-related hepatocellular carcinoma (HCC) …
virus (HCV) infection, the number of cases of HCV-related hepatocellular carcinoma (HCC) …
Safety and pharmacokinetics of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infections and compensated liver disease
E Gane, F Poordad, N Zadeikis, J Valdes… - Clinical Infectious …, 2019 - academic.oup.com
Background Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive
liver damage, which can be mitigated by successful treatment. This integrated analysis …
liver damage, which can be mitigated by successful treatment. This integrated analysis …
[HTML][HTML] Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers
CH Cheng, CY Chu, HL Chen, IT Lin, CH Wu… - Journal of the Formosan …, 2021 - Elsevier
Background/Purpose Direct-acting antiviral agents achieve sustained virological response
in most chronic hepatitis C patients. However, histological responses are not consistent …
in most chronic hepatitis C patients. However, histological responses are not consistent …
Strategies targeting the innate immune response for the treatment of hepatitis C virus-associated liver fibrosis
D Sepulveda-Crespo, S Resino, I Martinez - Drugs, 2021 - Springer
Direct-acting antivirals eliminate hepatitis C virus (HCV) in more than 95% of treated
individuals and may abolish liver injury, arrest fibrogenesis, and reverse fibrosis and …
individuals and may abolish liver injury, arrest fibrogenesis, and reverse fibrosis and …
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
A Naganuma, K Chayama, K Notsumata… - Journal of …, 2019 - Springer
Background Chronic hepatitis C virus (HCV) infection with genotypes (GT) 1 and 2 accounts
for over 50% of HCV infections globally, including over 97% of all HCV infections in Japan …
for over 50% of HCV infections globally, including over 97% of all HCV infections in Japan …
Efficacy and safety of 8 weeks of glecaprevir/pibrentasvir in treatment-naïve, HCV-infected patients with APRI≤ 1 in a single-arm, open-label, multicenter study
RJ Fontana, S Lens, S McPherson, M Elkhashab… - Advances in …, 2019 - Springer
Introduction The presence or absence of cirrhosis in patients with chronic hepatitis C virus
(HCV) infection influences the type and duration of antiviral therapy. Non-invasive markers …
(HCV) infection influences the type and duration of antiviral therapy. Non-invasive markers …
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
Ó Brochado, I Martínez, J Berenguer… - Journal of Biomedical …, 2021 - Springer
Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-
based therapy on gene expression profiles related to the immune system in HIV/HCV …
based therapy on gene expression profiles related to the immune system in HIV/HCV …